Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 4/20 | 0.45 |
| ▸ | F2 | P00734 | 2/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | RXRG | P48443 | 1/20 | 0.43 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.42 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.42 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amelubant SCHEMBL13696755 | 0.80 | MAOB (0.45) | PTPRCPTPN1MAOBF2MRGPRX4 | |
| Amelubant SCHEMBL1891672 | 0.80 | MAOB (0.45) | PTPRCPTPN1MAOBF2MRGPRX4 | |
| SCHEMBL8378348 | 0.79 | F2 (0.51) | PTPRCPTPN1MAOBF2MRGPRX4 | |
| SCHEMBL8378347 | 0.79 | F2 (0.51) | PTPRCPTPN1MAOBF2MRGPRX4 | |
| SCHEMBL13140115 | 0.78 | F2 (0.53) | PTPRCPTPN1MAOBF2MRGPRX4 | |
| SCHEMBL31506335 | 0.78 | F2 (0.72) | F2 | |
| SCHEMBL4999957 | 0.78 | F2 (0.72) | F2 | |
| SCHEMBL5200582 | 0.78 | PTPRC (0.46) | PTPRCPTPN1MAOBF2FFAR1 | |
| Hydrochloric Acid SCHEMBL6557386 | 0.77 | F2 (0.73) | F2 | |
| SCHEMBL8378355 | 0.76 | MAOB (0.47) | PTPRCPTPN1MAOBF2MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050129768-A1 | Pharmaceutical formulation containing an LTB4-antagonist, as well as processes for the preparation thereof and the use thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-06-16 | — | — | US | claimed |
| US-20050129768-A1 | Pharmaceutical formulation containing an LTB4-antagonist, as well as processes for the preparation thereof and the use thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-06-16 | — | — | US | disclosed |
| US-20050095293-A1 | Administration form for the oral application of poorly soluble drugs | BOEHRINGER INGELHEIM PHARMA GMBH CO. KG (DE) | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050129768-A1 | Pharmaceutical formulation containing an LTB4-antagonist, as well as processes for the preparation thereof and the use thereof | LTB4R, LTB4R2, LTA4H | PTPRC 3233/4885PTPN1 1940/4885MAOB 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.